Provider costs of treating opioid dependence with extended-release buprenorphine in Australia.

Autor: Settumba S; National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia., Shahbazi J; National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia., Byrne M; National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia., Degenhardt L; National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia., Grebely J; The Kirby Institute, UNSW Sydney, Sydney, Australia., Larance B; National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.; School of Psychology, University of Wollongong, Wollongong, Australia.; Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, Australia., Nielsen S; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia.; Monash Addiction Research Centre and Eastern Health Clinical School, Monash University Peninsula Campus, Melbourne, Australia., Lintzeris N; Discipline of Addiction Medicine, The University of Sydney, Sydney, Australia.; The Langton Centre, Southeast Sydney Local Health District, Sydney, Australia., Ali R; National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia., Rodgers C; Rankin Court Treatment Centre, The O'Brien Centre, Sydney, Australia., Blazey A; Royal North Shore Hospital, North Sydney Local Health District, Sydney, Australia., Weiss R; Frankston Healthcare, Melbourne, Australia., Dunlop A; Drug and Alcohol Services, Hunter New England Local Health District, Newcastle, Australia.; Hunter Medical Research Institute, University of Newcastle, Newcastle, Australia., McDonough M; Drug and Alcohol Services South Australia, Adelaide, Australia., Cook J; Drug and Alcohol Clinical Advisory Service, Western Health, Melbourne, Australia., Farrell M; National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.
Jazyk: angličtina
Zdroj: Drug and alcohol review [Drug Alcohol Rev] 2024 Oct 06. Date of Electronic Publication: 2024 Oct 06.
DOI: 10.1111/dar.13956
Abstrakt: Introduction: The costs of providing medication-assisted treatment for opioid dependence can determine its scale of provision. To provide estimates of the costs of extended-release buprenorphine (BUP-XR), we performed a bottom-up costing analysis of provider operational treatment costs.
Methods: Data were collected in a single-arm open label trial of BUP-XR injections conducted in specialist public drug treatment services and primary care private practices in three Australian states (the CoLAB study). The unit costs of resources used for each activity were combined with quantities used at each participating facility to arrive at the average annual cost per client.
Results: One hundred participants across the six health facility sites received monthly subcutaneous BUP-XR injections administered by a health-care practitioner. The average cost of providing 1 year of treatment per participant was $6656 ($6026-$8326). Screening cost (initial assessment and medical history) was $282 while monthly follow-up appointments cost $531 per client. The main cost driver was the monthly treatment costs accounting for 79% of the average annual client cost, with medication costs comprising 95% of this cost.
Discussion and Conclusion: With medication costs making up the largest proportion of treatment costs, treatment using BUP-XR has the potential to free up other health system resources, for example, staff time. The costs reported in this study can be used in an economic evaluation to estimate the net benefit or cost-effectiveness of BUP-XR especially when compared to other opioid agonist treatments.
(© 2024 The Author(s). Drug and Alcohol Review published by John Wiley & Sons Australia, Ltd on behalf of Australasian Professional Society on Alcohol and other Drugs.)
Databáze: MEDLINE
Externí odkaz: